Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Safe Equitable Campus Resources and Education Act of 2019
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization. Sent letter to Senate Finance Committee Chair and Ranking Member submiting comments on the Chairman's Mark, "Prescription Drug Pricing Reduction (PDPRA) Act of 2019, Disseminated information on H.R. 2026 - "Pharmaceutical Information Exchange Act"
CREATES Act of 2019
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2019 · third_quarter · Q3
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing) and submitted letter to Senate Finance Committee Chair and Ranking Member on the Chairman's Mark, "Prescription Drug Pricing Reduction (PDPRA) Act of 2019"
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization. Sent letter to Senate Finance Committee Chair and Ranking Member submiting comments on the Chairman's Mark, "Prescription Drug Pricing Reduction (PDPRA) Act of 2019, Disseminated information on H.R. 2026 - "Pharmaceutical Information Exchange Act"
Source: Senate LDA
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing)
CREATES Act of 2019
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing) and submitted letter to Senate Finance Committee Chair and Ranking Member on the Chairman's Mark, "Prescription Drug Pricing Reduction (PDPRA) Act of 2019"
CREATES Act of 2019
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
Lower Health Care Costs Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing)
Lower Health Care Costs Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing) and submitted letter to Senate Finance Committee Chair and Ranking Member on the Chairman's Mark, "Prescription Drug Pricing Reduction (PDPRA) Act of 2019"
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing)
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing) and submitted letter to Senate Finance Committee Chair and Ranking Member on the Chairman's Mark, "Prescription Drug Pricing Reduction (PDPRA) Act of 2019"
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits.
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
Biologic Patent Transparency Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing)
Biologic Patent Transparency Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing) and submitted letter to Senate Finance Committee Chair and Ranking Member on the Chairman's Mark, "Prescription Drug Pricing Reduction (PDPRA) Act of 2019"
Biologic Patent Transparency Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2019 · second_quarter · Q2
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr at the June 23, 2019 Senate HELP hearing)
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2019 · first_quarter · Q1
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization. Meeting with the Department of Health and Human services on proposal to restrict the use of rebates under Medicare and Medicaid
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE